Regenerative medicine company Advanced Cell Technology (ACT) has appointed Paul Wotton CEO and president, six months after starting its search for a new leader. The firm’s most recent chief, Gary Rabin, left the company in January for unspecified reasons and, since then, Edward Myles, CFO and executive vice-president of corporate development, has been interim president. Mr Rabin took the reins in December 2010 after the sudden death of previous CEO William Caldwell. New leader Dr Wotton joins from Antares Pharma, where he has served as president and CEO since October 2008; before this, he was CEO of Topigen Pharmaceuticals and previously was the global head of business development of SkyePharma. Dr Wotton says ACT is at a “pivotal time,” about to go into Phase II clinical trials for age-related macular degeneration (AMD) and Stargardt’s macular dystrophy (SMD), Phase I for myopic macular degeneration (MMD), and to “advance the novel programs in its pre-clinical pipeline.”
Advanced Cell Technology grabs Antares CEO
Regenerative medicine company Advanced Cell Technology (ACT) has appointed Paul Wotton CEO and president, six months after starting its search for a new leader. The firm’s most recent chief, Gary Rabin, left the company in January for unspecified reasons and, since then, Edward Myles, CFO and executive vice-president of corporate development, has been interim president. Mr Rabin took the reins in December 2010 after the sudden death of previous CEO William Caldwell. New leader Dr Wotton joins from Antares Pharma, where he has served as president and CEO since October 2008; before this, he was CEO of Topigen Pharmaceuticals and previously was the global head of business development of SkyePharma. Dr Wotton says ACT is at a “pivotal time,” about to go into Phase II clinical trials for age-related macular degeneration (AMD) and Stargardt’s macular dystrophy (SMD), Phase I for myopic macular degeneration (MMD), and to “advance the novel programs in its pre-clinical pipeline.”
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.